Myopathies Associated With Monoclonal Gammopathies of Clinical Significance: A Narrative Review. [PDF]
Belkhribchia MR.
europepmc +1 more source
ABSTRACT Hereditary angioedema (HAE) with C1 inhibitor deficiency is a rare disease characterized by unpredictable episodes of tissue swelling (angioedema), which, in most cases, occur first under the age of 18 years, and entail a significant burden of disease not only for the patients but also for their families.
Henriette Farkas +128 more
wiley +1 more source
Genetic Spectrum and Phenotypic Variability in Chinese Patients with Multisystem Proteinopathy and Related Disorders. [PDF]
Xia X +8 more
europepmc +1 more source
A CASE REPORT OF HYPOKALEMIC MYOPATHY DUE TO INGESTION OF LARGE DOSES OF “JINTAN”
Kouichi Sugimoto +3 more
openalex +2 more sources
Positive Malignant Hyperthermia Susceptibility In Vitro Test in a Patient with Mitochondrial Myopathy and Myoadenylate Deaminase Deficiency [PDF]
Ruth Fricker +6 more
openalex +1 more source
Barramundi (Lates calcarifer) is an economically significant aquaculture species and ranks among Australia's top five farmed finfish. As global production intensifies, understanding the physiology and health of barramundi is essential to support animal welfare and industry profitability.
CY(V) Pang, N Courtman, F Samsing
wiley +1 more source
Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor? [PDF]
Lam B, Tiniakou E, Zhang XR, Assassi S.
europepmc +1 more source
Proteomics‐guided exome re‐analysis identifies bi‐allelic variants in the nuclear envelope LEMD2 gene, expanding its phenotypic spectrum. Created in BioRender. Pauper, M. (2026) https://BioRender.com/xamvo92.
Marc Pauper +17 more
wiley +1 more source
A Rare Case Report of Antisynthetase Syndrome With Progressive Myopathy and Interstitial Lung Disease in a 38-Year-Old Male. [PDF]
Ali M +4 more
europepmc +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source

